OptimizeRx announces changes to its Board of Directors reflecting a strategic move to further align with the company’s growth plans. After nearly a decade of service, Gus Halas is retiring from his position as Chairperson of the Board. Effective immediately, Lynn O’Connor Vos will assume the role of Chairperson of the Board, succeeding Halas. Vos has been a seasoned and respected member of the OptimizeRx Board since 2015. Further strengthening the Board’s expertise, OptimizeRx announces the appointment of Catherine Klema as a new member of the Board.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OPRX:
- OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape
- OptimizeRx price target raised to $17 from $14 at Lake Street
- OptimizeRx sees 2024 revenue at least $110M, consensus $110.29M
- OptimizeRx sees 2023 revenue exceeding $68M-$70M, consensus $68.78M
- OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business Update
